RECURSION PHARMACEUTICALS, INC. (RXRX) 8-K Current Report: February 25, 2026
Filed: February 25, 2026
Health Care
Biological Products, (No Diagnostic Substances)RECURSION PHARMACEUTICALS, INC. (RXRX) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
RECURSION PHARMACEUTICALS, INC. 8-K Feb 25, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year fiscal 2025 earnings released February 25, 2026
- • Full results in Exhibit 99.1 — primary source for revenue, cash position, and pipeline spend details
Item 7.01 · Regulation FD Disclosure
- • Recursion released an earnings presentation on Feb 25, 2026 in connection with its Q4/FY earnings call
- • Full presentation details in Exhibit 99.2 — key metrics and pipeline updates available there
- • Company uses SEC filings, IR website, press releases, and social media as official investor communication channels
Get deeper insights on RECURSION PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.